Drug Trial Radar · NCT06377228
A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)
Last checked: Nov 19, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jun 13, 2025
Primary completion
Sep 2, 2030
Study completion Sep 2, 2030
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Apr 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of the trial is to learn how well adults with refractory lupus nephritis (LN) or refractory systemic sclerosis (SSc) tolerate TAK-007 and to check for side effects (adverse events). Other aims are to learn how effective treatment with TAK-007 is in adults with refractory LN or refractory SSc, what effects TAK-007 has on the human body, and whether participants will produce antibodies against TAK-007.
Conditions
- Refractory Lupus Nephritis
- Refractory Systemic Sclerosis
Interventions
TAK-007Biological
TAK-007 IV infusion.
Chemotherapy AgentsDrug
Fludarabine and cyclophosphamide IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of LDC up to end of study (EOS) [up to Month 24]
- Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to Day 30
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Texas Health Science Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.